Home » Topics » Regulatory » EMA

EMA
RSS

MAA for ceftobiprole in pneumonia accepted for review under E.U. decentralized procedure

Oct. 8, 2012

EMA determines Sufentanil NanoTab PCA System eligible for centralized review

Oct. 5, 2012

Ariad completes rolling NDA submission for ponatinib

Oct. 1, 2012

EMA recommends approval of ingenol mebutate for actinic keratosis

Sep. 28, 2012

Regeneron's Eylea receives second U.S. approval

Sep. 27, 2012

Votubia recommended for approval in Europe

Sep. 26, 2012

EMA committee recommends approval of enzyme-based debriding agent for burn care

Sep. 26, 2012

Avastin recommended for approval of recurrent, platinum-sensitive ovarian cancer in Europe

Sep. 26, 2012

Novartis obtains positive CHMP opinions for Galvus and Eucreas

Sep. 26, 2012

CHMP gives positive opinion on Cialis in new indication

Sep. 26, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.